FDA Clears Four New Drugs in Three Days, Pushing 2026 Novel Approvals to 54, as Lilly and J&J Line Up $10.7 Billion in Biotech Deals

The U.S. Food and Drug Administration has spent this week clearing new medicines at a pace that is hard to ignore. Between Monday and Wednesday, the agency approved four novel drugs, taking its 2026 tally of novel approvals to 54, according to the FDA’s running list of novel drug approvals. At the same time, Eli Lilly and Johnson & Johnson announced biotech deals worth up to roughly $10.7 billion combined, a reminder that big pharma is paying up for the next wave of medicines even as this one reaches the market.

For business readers, the two threads belong in the same story. Approvals turn research spending into revenue, and deal-making is how large drugmakers restock pipelines once those products are launched. This week showed both engines running at once.

Four Approvals, Three Days

The FDA’s novel approvals list shows the following new molecular entities cleared this week:

  • Wilserdly (giredestrant), Roche, November 16. Approved in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after endocrine-based therapy. Roche describes it as a next-generation oral SERD, a pill that degrades the estrogen receptor driving these tumors.
  • Nelkarmi (neladalkib), GSK, November 17. An accelerated approval for previously treated ALK-positive non-small cell lung cancer. GSK said the decision came ahead of the FDA’s original target date of November 27 and is its second lung cancer approval this year.
  • Lembaz (adrabetadex), Beren Therapeutics, November 17. The FDA said it is the first drug shown to help patients with infantile-onset Niemann-Pick disease type C live longer. It is given intrathecally every two weeks and requires hearing checks because permanent hearing loss can occur.
  • Infilbray (venglustat), Sanofi, November 18. A once-daily oral drug and, per Reuters, the first treatment for the neurological symptoms of type 3 Gaucher disease, a rare inherited disorder in which fatty substances build up in the body and brain. It is approved for adults and children weighing at least 15 kilograms.

What the Nelkarmi Data Shows

GSK’s release gives a useful window into what regulators accepted for an accelerated approval. In patients whose only prior ALK inhibitor was alectinib, the confirmed overall response rate in the phase I/II ALKOVE-1 trial was 49% (33 of 67 patients). In more heavily treated patients who had received two or more ALK inhibitors plus chemotherapy, it was 32% (50 of 155). Among patients with measurable brain metastases, intracranial response rates were 55% and 26% in those two groups, respectively, which matters because lung cancer often spreads to the brain. GSK reported that 5% of patients stopped treatment permanently because of side effects, most often liver toxicity.

Accelerated approvals are granted on early evidence such as response rates, and they typically come with a requirement to confirm benefit in further studies. For investors, that means the commercial runway is real but conditional.

The Deal Machine Keeps Running

The approvals arrived alongside a cluster of transactions reported by Reuters:

  • Eli Lilly and Stipple Bio: an oncology research and licensing agreement worth up to $5.9 billion, giving Lilly access to technology designed to find molecules that distinguish cancer cells from healthy tissue.
  • Johnson & Johnson and Ollin Biosciences: an agreement to buy the Texas-based eye disease biotech for up to $3.33 billion, adding the experimental treatment OLN324 in an area where J&J has a limited footprint outside contact lenses.
  • Eli Lilly and Calytrix Bio: an acquisition for up to $1.5 billion in cash, aimed at rare blood cancers.

Not every headline was positive. Reuters also reported that Merck is halting development of its experimental blood cancer drug nemtabrutinib after an independent review found its benefits may not outweigh its risks, a reminder that late-stage failures remain one of the industry’s biggest costs.

Why It Matters for Business

Rare disease and oncology dominate. Three of this week’s four approvals target cancer or ultra-rare genetic conditions. These markets have small patient populations but strong pricing power, regulatory incentives such as orphan drug designation (Nelkarmi carried both Breakthrough Therapy and Orphan Drug designations, according to GSK), and less direct competition. That mix explains why so much capital, including Lilly’s Calytrix bet, keeps flowing toward them.

Early decisions are worth money. When the FDA acts ahead of a target date, as it did with Nelkarmi, the company can begin selling sooner. Each week of earlier launch matters most for drugs whose patent clocks are already running.

Milestone-heavy deals spread the risk. The “up to” language in the Lilly and J&J announcements signals that much of the headline value depends on future clinical or commercial milestones. Buyers pay less upfront and more only if the science works, which is a sensible structure in a business where programs like nemtabrutinib can stop late in development.

Downstream demand follows approvals. New therapies create work for specialty pharmacies, infusion and treatment centers, diagnostic labs that test for markers such as ESR1 mutations or ALK rearrangements, and patient support services that help families navigate coverage. Businesses in that ecosystem should watch the FDA calendar as closely as the drugmakers do.

The Bottom Line

Four novel approvals in three days and around $10.7 billion in potential deal value in the same week show a drug industry that is still converting science into products and still willing to pay for what comes next. The approvals bring new options to patients with breast cancer, lung cancer and two rare inherited diseases, while the deals and Merck’s setback show how expensive and uncertain the road to the next approval remains.

Sources: FDA Novel Drug Approvals 2026, FDA press announcement on Lembaz, GSK release via Reuters/TradingView, Reuters via MSN on Infilbray, Roche media release, Reuters Health News Summary.

Never miss a patient or customer call. When new treatments launch, clinics, pharmacies and patient support teams see call volumes jump. MAJ.COM Voice AI gives you 24/7 AI voice agents that answer every inbound call and handle outbound sales and customer support, so your business never misses a lead.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 185 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading